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Abstract
Nuclear receptor 4a3 (Nr4a3) is a transcription factor implicated in various settings such as vascular biology and
inflammation. We have recently shown that mast cells dramatically upregulate Nuclear receptor 4a3 upon activation, and
here we investigated the functional impact of Nuclear receptor 4a3 on mast cell responses. We show that Nuclear receptor
4a3 is involved in the regulation of cytokine/chemokine secretion in mast cells following activation via the high affinity IgE
receptor. Moreover, Nuclear receptor 4a3 negatively affects the transcript and protein levels of mast cell tryptase as well as
the mast cell’s responsiveness to allergen. Together, these findings identify Nuclear receptor 4a3 as a novel regulator of
mast cell function.
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influenced by cellular location, which might be regulated by
phosphorylation [14]. Members of the Nr4a family partake in
many cellular responses, including those affecting the immune
system and inflammation as shown by the contribution of Nr4a1
and Nr4a3 to induction of T-cell and macrophage apoptosis [14–
16]. Moreover, cytokine and chemokine responses are regulated
by Nr4a family members in both macrophages and T-cells,
lending additional support of their role in immunomodulation
[17,18].
In a previous study where the global impact of bacterial
infection on mast cell responses was studied, it was noted that
exposure of mast cells to gram-positive Streptococci resulted in a
dramatic upregulation of all three Nr4a members, with the most
striking increase noted for Nr4a3 [19]. In a subsequent study we
showed that Nr4a members, in particular Nr4a3, were strongly
induced also by mast cell activation through FceRI crosslinking
[20]. Prompted by these findings, we here investigated the
functional impact of Nr4a3 on mast cells. We show that Nr4a3
is required for optimal cytokine generation following antigeninduced mast cell activation. Moreover, we show that the presence
of Nr4a3 regulates FceRI-mediated degranulation, and finally we
show that Nr4a3 selectively suppresses the transcript and the
resulting protein of the tryptase mouse mast cell protease 6
(mMCP-6; encoded by Tpsb2). Together, these findings suggest a
hitherto unrecognized role of Nr4a3 in regulating mast cell
homeostasis and activation.

Introduction
Mast cells are important components of the innate and
adaptive immune system, most notably taking part in the
defense against parasites, bacteria and viruses [1,2]. However,
there are also several detrimental effects associated with mast
cells, e.g. allergy and rheumatoid arthritis [1,2]. The mast cell
expresses the high affinity IgE-receptor, FceRI. FceRI ecrosslinking, e.g. by an allergen, results in the immediate release of
preformed mediators that are stored in secretory granules [3]
and also to the activation of transcriptional events, e.g.
mediated by NFAT, NFkB and AP-1, leading to cytokine
generation and release. Mast cells are broadly divided into
mucosal and connective tissue types based on their repertoire of
expressed proteases, for instance chymase, tryptase and
carboxypeptidase A3 (CPA3) type, though how the expression
of these proteases is regulated is poorly understood [1,2,4].
Transcriptional regulation involving GATA-1, FOG and MITF
is also an essential part of the development of the mast cell into
its different subtypes [5,6], and mast cell development and
phenotype is additionally influenced by the cytokine and growth
factor milieu in the respective tissues [7,8].
The nuclear receptor subfamily 4a (Nr4a) encompasses three
members, Nur77/Nr4a1, Nurr1/Nr4a2 and NOR-1/Nr4a3, which
are early response genes reacting to a variety of stimuli such as
cytokines, infectious agents, growth factors and cellular stress [9–
13]. The activities of the Nr4a3 family members are ligandindependent, meaning that once translated they do not require
further stimuli to exert their function. However, their activity is
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Cell Culture

Table 1. Primers used for qPCR.

Target

Bone-marrow cells from C57BL/6 mice were obtained from
femural and tibial bone of wild type (WT) and Nr4a32/2 [21]
mice and cultured in DMEM, supplemented with 10% heatinactivated fetal bovine serum, 60 mg/ml Penicillin, 50 mg/ml
Streptomycinsulfate, 2 mM l-glutamine and 10 ng/ml recombinant IL-3 (Peprotech). The cells were kept at a concentration of
0.5–16106 cells/ml with weekly changes of medium [22].

Sequence

mouse
Hprt, fwa

59-GAT TAG CGA TGA TGA ACC AGG TTA-39

Hprt, revb

59-GAC ATC TCG AGC AAG TCT TTC AGT C-39

Srgn, fw

59-GCA AGG TTA TCC TGC TCG GAG-39

Srgn, rev

59-GGT CAA ACT GTG GTC CCT TCT C-39

Mast Cell Activation

Tpsb2, fw

59-CAT TGA TAA TGA CGA GCC TCT CC-39

Tpsb2, rev

59-CAT CTC CCG TGT AGA GGC CAG-39

Mcpt4, fw

59-GAA GCT TCA AAA GAA-39

Mcpt4, rev

59-GGT TCT GTC ACT CCA-39

Cpa3, fw

59-TGA CAG GGA GAA GGT ATT CCG-39

Cpa3, rev

59-CCA AGG TTG ACT GGA TGG TCT-39

For IgE-induced activation, cells were sensitized with anti-TNP
IgE at 1 mg/ml overnight, washed, resuspended in new media and
stimulated with TNP-OVA (0.4 mg/ml or indicated concentrations) [22]. Cells were collected at various time points by
centrifugation; media and cell fractions were frozen and stored
at 220uC. The effect on TNFa, MCP-1, IL-6 and IL-13 release
was determined in cell supernatants using ELISA as detailed by
the manufacturer.

All primers were designed using the software Primer Express Version 1.0.
a
fw, forward primer,
b
rev, reverse primer.
doi:10.1371/journal.pone.0089311.t001

b-Hexosaminidase Activity
b-Hexosaminidase activity was measured in solubilized cell
pellets and supernatants from resting or activated cells as described
[22].

Materials and Methods
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
institutional animal care and use committee at the University of
Kentucky approved all procedures on mice. The animals were
maintained and treated according to the guidelines set by IACUC.
Euthanasia was carried out using CO2 according to AVMA
Guidelines for the Euthanasia of Animals.

Cell Lysate
Lysate buffer (200 ml PBS, 2 M NaCl, 0.5% Triton X-100) was
added to cell pellets (16106 cells/pellet) followed by vortexing.
The protein concentration in the lysates was determined with the
Bradford method using BSA as a standard. The determined
protein concentration was used for normalizing the enzyme
activity and Western blot protein loading. Samples used for
Western Blot analysis were treated with protease and phosphatase
inhibitors.

Reagents
Polyclonal antibodies against mMCP-6 (encoded by Tpsb2), and
CPA3 were raised in rabbits [22]. Antibodies from Cell Signaling
were purchased to identify NFAT1 (5861), Fyn (4023), Lyn (2796),
IKKb (2370) and IKKa (2682). Rabbit polyclonal antibody
towards b-actin (sc-130656) was from Santa Cruz. ELISA kits
were from eBioscience (MCP-1, IL-6, IL-13) and Peprotech
(TNFa), respectively.

Enzymatic Activity
Duplicate samples of cell lysate (20 ml) were mixed with 80 ml
H2O to which 20 ml of a 2 mM solution (in H2O) of the
chromogenic substrate S-2288 (H-D-Isoleucyl-L-prolyl-L-arginine-p-nitroaniline dihydrochloride; Chromogenix) was added.
Changes in absorbance were recorded at 405 nm and used to
calculate initial reaction velocities.

Figure 1. Nr4a3 does not affect mast cell development. (A, B) Toluidine blue staining of WT (A) and Nr4a32/2 (B) mast cells after 4 weeks of
culture. Note that the absence of Nr4a3 does not affect the morphology or granular staining of the cells.
doi:10.1371/journal.pone.0089311.g001
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Figure 2. Nr4a3 affects cytokine/chemokine secretion in response to FceeRI cross-linking. (A–D) WT and Nr4a32/2 mast cells were
incubated with TNP-specific IgE over-night followed by activation for 4 hours or 24 hours with TNP-OVA as indicated. Supernatants were analyzed for
levels of MCP-1 (A), TNFa (B), IL-6 (C) and IL-13 (D) by ELISA (T-test, n = 4; *p#0.05). The lack of Nr4a3 is associated with a reduction in cytokine release
following FceRI cross-linking.
doi:10.1371/journal.pone.0089311.g002

washing with TBS/0.1% Tween-20, the membranes were
incubated with appropriate secondary antibodies conjugated to
IRDye 800 or IRDye 680 (diluted 1:1000 in Odyssey Blocking
Buffer:TBS) for 1 h at room temperature. The membranes were
subsequently washed twice in TBS/0.1% Tween-20 and once in
TBS before detecting the signal using an Odyssey Infrared
Imaging System (Li-Cor Biosciences, 9201-01).

Induction of Cell Death
Triplicates of 1 ml BMMCs (0.56106 cells/ml) were transferred
into individual wells of a 24-well flat-bottomed plate, and were
either left untreated or treated with cytotoxic agents: L-Leucyl-LLeucine methyl ester (LLME, 200 mM), Cycloheximide (CHX,
5 mg/ml) or H2O2 (0.75 mM) in complete culture medium,
followed by incubation for different time periods (as specified in
the figure legends). Triplicates of 100 ml of cell suspension were
transferred into a 96-well plate and cell viability was measured
using CellTiter-Blue reagent (Promega-Invitogen, Carlsbad, CA).
The plate was read using a microplate reader (Infinite M200–
TECAN) at 560 nm (excitation) and 590 nm (emission).

Quantitative Real Time RT-PCR
Total RNA preparation and quantitative real-time PCR (qPCR)
were performed as previously described [23]. For primers used, see
Table 1.

Western Blot

Statistical Analysis

Cell lysates were mixed with 46 reducing SDS-PAGE sample
buffer and subjected to SDS–PAGE on 12% gels. Thereafter,
proteins were blotted onto PVDF membranes, followed by
blocking in Odyssey Blocking Buffer diluted 1:1 in TBS for 1 h.
Next, the membranes were incubated with primary antibodies
(diluted 1:500 for mMCP6, diluted 1:1000 for all others) in
Odyssey Blocking Buffer:TBS (1:1), overnight at 4uC. After

Statistical analyses using two tailed, Student’s t-test or ANOVA
were performed using GraphPad Prism 4. Differences were
considered significant if the p-values were 0.05 or less. All
experiments were repeated at least three times; representative
experiments are displayed.
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Figure 3. Nr4a3 modulates signaling pathways involved in mast cell degranulation (A–F). (A–B) Whole cell lysates from resting WT and
Nr4a32/2 mast cells were prepared and analyzed by Western blot for the Src-kinases Fyn (A) and Lyn (B). The signal was compared against b-actin
followed by normalization using the average signal from WT samples set to 1. (C–D) Graphical representation of the densitometric analysis for Fyn (C)
and Lyn (D) (T-test, n = 4; *p#0.05). (E) WT and Nr4a32/2 mast cells were incubated with TNP-specific IgE over-night followed by activation for 30
minutes with increasing amounts of TNP-OVA. Supernatants were collected and were analyzed for b-hexosaminidase activity as a measure of the
extent of degranulation. (ANOVA, n = 4; *p#0.05). (F) Whole cell lysates were prepared and analyzed for their b-hexosaminidase content.
doi:10.1371/journal.pone.0089311.g003

Nr4a3-deficient mast cells (Fig. 1A–B), suggesting that Nr4a3 does
not affect mast cell development.
In a previous study we found that the Nr4a3 transcript was
potently upregulated following FceRI crosslinking, suggesting that
Nr4a3 might participate in the regulation of this pathway [20].
The events triggered by FceRI crosslinking include cytokine/
chemokine induction as well as degranulation whereby the
contents of the mast cell secretory granules (e.g. b-hexosaminidase,
proteases and biogenic amines) are released. To explore the
potential role of Nr4a3 in regulating these processes we first
studied the effect of Nr4a3-deficiency on the secretion of IL-6, IL-

Results and Discussion
Nr4a3 is Required for Optimal FceRI-induced Cytokine/
Chemokine Generation in Mast Cells
To study the influence of Nr4a3 on mast cell function we
cultured bone-marrow cells isolated from WT and Nr4a3-deficient
mice in the presence of IL-3, which results in maturation of
precursor cells into mast cells, i.e. bone marrow-derived mast cells
(BMMCs). Toluidine blue staining of four-week old cultures
showed no apparent morphological differences between WT and
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response to FceRI crosslinking, thus indicating that Nr4a3
promotes the induction of these factors. In turn, this suggests that
Nr4a3 may have a pro-inflammatory role in terms of regulating
cytokine/chemokine responses in a mast cell setting. The findings
are in line with previous studies in which Nr4a family members
have been implicated in the regulation of inflammatory gene
expression in macrophages activated through pattern recognition
receptors [18].
The canonical NFkB-pathway has been implicated in antigeninduced generation of various cytokines in mast cells [24]. It has
been shown that Nr4a-members influence NFkB-signaling by
modulating the expression of components of the Inhibitor of
nuclear factor-kB-kinase (IKK) complex in macrophages [18]. In
mast cells, IKKa and IKKb have been shown to be important for
cytokine generation following antigen activation [24,25]. Nr4a3mediated effects on the expression of IKKa and IKKb could
therefore potentially explain the reduced cytokine response in mast
cells devoid of Nr4a3. We thus measured the levels of IKKa and
IKKb in mast cells but found that neither the IKKa nor the IKKb
levels were significantly altered due to Nr4a3 deficiency (data not
shown). The major pathway for FceRI-induced IL-13, MCP-1 and
TNFa generation in mast cells involves transcription factors
belonging to the Nuclear Factor of Activated T cells (NFAT)
family [20,26]. We therefore explored the possibility that the lack
of Nr4a3 influenced the protein levels of NFAT1 in mast cells, but
could not detect any significant change (data not shown).
The earliest event following FceRI crosslinking is activation of
the Src-family kinases Lyn and Fyn, which phosphorylate the
immunoreceptor tyrosine-based activation motifs of the b and c
subunits of FceRI [27,28]. Both Lyn and Fyn are positive
regulators of the downstream signaling cascade leading to
degranulation and cytokine generation. When determining the
total levels of Fyn and Lyn we found that Nr4a3 deficiency was
associated with reduced Fyn expression whereas Lyn was
unaffected (Fig. 3A–D). In mast cells, Lyn and Fyn both propagate
the signal via Syk but Fyn also utilizes pathways involving
phosphatidylinositol 3-kinase (PI3K) or Stat5 [29,30]. Future
investigations will determine which signaling pathway is affected
by the Nr4a3 dependent reduction in Fyn levels. Nevertheless, the
reduction in Fyn levels could be one explanation for the reduced
cytokine generation in Nr4a3 deficient mast cells, but a direct
effect of Nr4a3 on cytokine transcription cannot be ruled out.
To further assess whether Nr4a3 influences the degree of FceRIinduced activation, we determined whether the actual extent of
degranulation in response to FceRI crosslinking was affected by
the absence of Nr4a3. To this end we measured the release of bhexosaminidase. Interestingly, in dose-response experiments with
increasing concentrations of antigen, Nr4a32/2 mast cells
exhibited an increased reactivity to antigen as illustrated by the
augmented release of b-hexosaminidase from activated Nr4a3deficient mast cells compared to their WT counterparts (Fig. 3E).
A possible explanation for this finding would be that Nr4a3 affects
the production and storage of b-hexosaminidase. However, total
b-hexosaminidase activity determinations showed that WT and
Nr4a32/2 mast cells were indistinguishable (Fig. 3F). Taken
together, these findings thus indicate that Nr4a3 influences
processes leading to degranulation.
Previous studies have implicated Nr4a family members, in
particular Nr4a1 and Nr4a3, in apoptosis [14–16]. It was therefore
of interest to investigate whether the absence of Nr4a3 affects
apoptosis in a mast cell context. To address this, mast cells were
subjected to the pro-apoptotic agents cycloheximide, H2O2 or LLeucyl-L-Leucine methyl ester (LLME) followed by measurements
of viability [31–33]. Interestingly, we found that Nr4a3-deficient

Figure 4. (A–C) Nr4a3-deficient mast cells are more susceptible
than WT cells to cell death induced by granule disruption. WT
and Nr4a32/2 mast cells were treated with 200 mM LLME (A), 5 mg/ml
Cycloheximide (B) or 0.75 mM H2O2 (C). The viability was determined at
the indicated time-points using CellTiter-Blue reagent (ANOVA, N = 6,
*p#0.05).
doi:10.1371/journal.pone.0089311.g004

13, MCP-1 and TNFa, based on the known importance of these
cytokines/chemokines in mast cell responses [1]. As seen in
Fig. 2A–D, the absence of Nr4a3 led to a significant reduction in
the secretion of the investigated cytokines and chemokines in
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Figure 5. Nr4a3 regulates the transcription of mast cell granule components. Total RNA was extracted from WT and Nr4a32/2 mast cells
followed by qPCR analysis for levels of mRNA encoded by Srgn (A), Mcpt4 (B), Tpsb2 (C) and Cpa3 (D). Hprt was used as house-keeping gene; transcript
data were calculated according to DDCT relative to the expression in WT cells (T-test, n = 4; *p#0.05).
doi:10.1371/journal.pone.0089311.g005

increase in the levels of trypsin-like enzymatic activity, as judged
by the rate of turn-over of a chromogenic substrate for trypsin-like
proteases such as mMCP-6 (Fig. 6 C). Considering that tryptase is
one of the most abundant proteins in mast cells [4,37], the
approximately 2-fold increase in transcript and activity represents
a quite substantial change. Based on the notion that mast cell
proteases promote cell death, it is plausible that the increased
susceptibility of Nr4a3-deficient mast cells to LLME-induced cell
death is due to their augmented levels of tryptase.
The expression of the mMCP-6 gene (Tpsb2) is governed by
MITF, PEBP2/CBF and c-jun, which independently or synergistically regulate Tpsb2 transcription [38–40]. Based on our results it
is thus plausible that Nr4a3 either acts as a repressor by directly
binding to the Tpsb2 promoter region, or indirectly by negatively
influencing the levels of MITF, PEBP2/CBF and/or c-jun.
Tryptase is viewed as an important molecule in a number of
inflammatory conditions where its presence either is beneficial
[41] or detrimental [42,43]. Thus, the suppressive influence of
Nr4a3 on Tpsb2 transcription may have important consequences
for the outcome of inflammatory settings in which tryptase
participates.
The present study identifies a novel role for Nr4a3 in regulating
mast cell responses, which is summarized in Fig. S1. Intriguingly,
our data suggest that although Nr4a3 promotes the secretion of
pro-inflammatory cytokines and chemokines, it exerts a negative
influence on pathways leading to degranulation responses and the
expression of one of the major granule compounds (mMCP-6).
Taken together, the differential influence Nr4a3 has on cytokine
generation and tryptase levels suggests that Nr4a3 is involved in
several regulatory pathways important for mast cell function. It is
thus conceivable that Nr4a3 has a role in regulating the balance
between different arms of responses induced by mast cell

mast cells were more susceptible to LLME-induced cell death than
were WT cells, whereas no difference in sensitivity to cycloheximide and H2O2 was seen when comparing WT and Nr4a32/2
mast cells (Fig. 4A–C). We have recently shown that tryptase, and
other serglycin-dependent proteases, induce cell death when
released into the cytosol following exposure to the lysosomotropic
compound LLME [32,34]. Changes in protease levels due to the
lack of Nr4a3 could hence explain the difference in susceptibility
to LLME-induced cell death.

Nr4a3 Regulates the Transcription of Serglycin and the
Tryptase Tpsb2
A characteristic feature of mast cells is their secretory granules
containing vast amounts of histamine alongside mast cell-specific
proteases, the latter requiring serglycin proteoglycan to be stored
[35,36]. To investigate if Nr4a3 influences mast cell function by
regulating the mast cell-specific proteases and serglycin proteoglycan, we performed qPCR determinations of transcripts for
serglycin (Srgn), chymase (Mcpt4), tryptase (Tpsb2; encoding
mMCP-6) and CPA3 (Cpa3) in WT and Nr4a32/2 mast cells
(Fig. 5A–D) using the primers specified in Table 1. We found that
Nr4a3 deficiency led to an ,2-fold increase in Tpsb2 transcript
levels and to a minor, but significant, reduction of Srgn transcript,
whereas the expression of Mcpt4 and Cpa3 were unaffected.
To elucidate if the effects on transcription translate into a
change in protein levels we performed Western blot analysis on
cell lysates from WT and Nr4a32/2 mast cells (Fig. 6 A–B). In
accordance with the mRNA expression analysis, the levels of
mMCP-6 protein were significantly higher in Nr4a32/2 mast cells
than in WT counterparts. Moreover, the increase in mMCP6 mRNA and protein was accompanied by a corresponding
PLOS ONE | www.plosone.org
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Figure 6. Nr4a3 suppresses the levels of tryptase protein and enzymatic activity. (A) Whole cell lysates from WT and Nr4a32/2 mast cells
were prepared and analyzed by Western blot for mMCP-6 and CPA3 as indicated (the upper and lower panels represent individual analyses,
performed on the same membrane that was stripped of protein between analyses). The absence of Nr4a3 results in increased levels of mMCP-6 but
does not affect CPA3. (B) Quantification of band intensities for mMCP-6 showing a significant increase in mMCP-6 protein in the absence of Nr4a3.
(n = 4; *p#0.05). The level of mMCP-6 and CPA3 proteins were quantified and compared against b-actin followed by normalization using the average
signal from WT samples set to 1. (C) Whole cell lysates from WT and Nr4a32/2 mast cells were prepared and analyzed for trypsin-like activity using the
chromogenic substrate S-2288. Note that the absence of Nr4a3 results in increased trypsin-like enzymatic activity. (T-test, n = 4; *p#0.05).
doi:10.1371/journal.pone.0089311.g006

activation, by promoting degranulation-independent events (cytokine/chemokine secretion) in favor of degranulation and expression of certain granule-localized proteases. It is important to stress
that mast cell degranulation, although essentially regarded as a

PLOS ONE | www.plosone.org

pro-inflammatory event, also has important regulatory consequences through the proteolytic inactivation of pro-inflammatory
cytokines by proteases released by degranulation [44–47]. The
present study has focused on how Nr4a3 influences the antigen-
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induced responses in mast cells and thus its implications for
allergies. Based on the findings in the present investigation it is
plausible that interfering with Nr4a3 function may augment
immediate hypersensitivity reactions as a result of increased mast
cell degranulation, whereby mediators such as histamine are
released. However, to fully comprehend the influence of Nr4a3 on
mast cell function in allergic reactions, additional research in
animal models of allergy is warranted.

and Srgn whereas Tpsb2 transcription is suppressed. In mast cells
activated by FceRI cross-linking, Nr4a3 promotes the synthesis
and release of cytokines but impairs events leading to degranulation.
(TIF)
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Figure S1 Summary of the findings presented in this
article. In resting mast cells, Nr4a3 augments transcription of Fyn
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